Bradley Pharmaceuticals Reports Strong First Quarter Earnings; Earnings Increase 90% In The Quarter.

FAIRFIELD, N.J.--(BUSINESS WIRE)--April 28, 1998--BRADLEY PHARMACEUTICALS, INC. (NASDAQ NMS: BPRX) today announced earnings of $404,000 or $0.04 per share (diluted) for the first quarter ended March 31, 1998. This compares with $212,000 or $0.03 (diluted) for the corresponding period last year, an earnings increase of approximately 90% resulting in an EPS increase of approximately 65%. Net sales for first quarter 1998 were over $4.2 million compared with less than $3.7 million for the same period last year, an increase of 16%.

First Quarter 1998 results were attributable primarily to an increase in the sales of the Company's existing Doak brands which have a lower margin compared to Kenwood's products, focused promotion and profitable contracting. First quarter results were also impacted by the reduction in amortization and decrease in interest expense.

Chairman and Chief Executive Officer, Daniel Glassman stated, "The Company, as of today, currently has $1.1 million in cash and has increased working capital by approximately $3.0 million in the past twelve months resulting in a positive position. This will provide sufficient capital to fund internal strategies, procedures and future developments. With a growing infrastructure and plans to increase the number of our total sales staff from 46 to 71 associates by the end of the year, we expect to strengthen our position in the competitive marketplace and further establish a stronger sales and marketing presence in the industry. The Company is directing its attention towards completing accretive acquisitions while continuing to build its current brands through niche marketing."

BRADLEY PHARMACEUTICALS, INC. manufactures and markets brandname products and over-the-counter pharmaceuticals and health-related products throughout the United States as well as in twenty-six international markets. Its Kenwood Laboratories division primarily markets respiratory therapy brands. Its Doak Dermatologics subsidiary markets products in the respiratory field and is involved in a research and development phase of corporate growth. Bradley Common A Shares (BPRX) are traded on the NASDAQ National Market System. -0- Please visit our website at www.bradpharm.com

This release may contain forward-looking statements which reflect management's current views of future events and operations. These forward-looking statements are based on assumptions and external factors, including assumptions relating to regulatory action, capital requirements and competing products. Any changes in such assumptions are external factors and could produce significantly different results. -0-

                        BRADLEY PHARMACEUTICALS
                        CONDENSED CONSOLIDATED
                       STATEMENTS OF OPERATIONS
                             (UNAUDITED)

                                      Three Months Ended
                                           March 31,
                                      1998          1997

Net sales                        $  4,241,281  $  3,671,649
Cost of sales                       1,314,797       854,517
                                    2,926,484     2,817,132

Selling, general and
 administrative expenses            1,970,327     1,946,149
Depreciation and amortization         273,434       405,688

Interest expense - net                 42,167       111,862
                                     2,285,928    2,463,699

Income before income taxes            640,556       353,433

Income tax                            237,000       141,000

Net income                       $    403,556  $    212,433

Net income per common share
  Basic                          $       0.05  $       0.03
  Diluted                        $       0.04  $       0.03

Weighted average number of
 common shares
   Basic                            8,463,000     8,087,000
   Diluted                          9,316,000     8,106,000

CONTACT: Daniel Glassman

Chairman and Chief Executive Officer

Bradley Pharmaceuticals, Inc.

[phone], Ext. 210

or

Cynthia DeMonte

DeMonte Associates

e-mail: [e-mail]

[phone]